c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma

Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53

(2014) Takumi Kumai et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor

(2014) Takumi Kumai et al.   Journal of Translational Medicine

The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

(2013) N. Miyajima et al.   CANCER RESEARCH

Effective Anti-Neu-Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells

(2013) E. D. Mortenson et al.   CLINICAL CANCER RESEARCH

Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer

(2013) I. Canadas et al.   CLINICAL CANCER RESEARCH

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

(2013) Yoon-Koo Kang et al.   INVESTIGATIONAL NEW DRUGS

Heat Shock Protein 90 Inhibitors Repress Latent Membrane Protein 1 (LMP1) Expression and Proliferation of Epstein-Barr Virus-Positive Natural Killer Cell Lymphoma

(2013) Takayuki Murata et al.   PLoS One

Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I-Modified Peptides

(2012) P. Filipazzi et al.   CLINICAL CANCER RESEARCH

Impact of Tumor Microenvironment and Epithelial Phenotypes on Metabolism in Breast Cancer

(2012) H. A. Brauer et al.   CLINICAL CANCER RESEARCH

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

(2012) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells

(2011) Seiko Iwata et al.   CANCER SCIENCE

Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study

(2011) Motoko Yamaguchi et al.   JOURNAL OF CLINICAL ONCOLOGY

Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer

(2011) Satoshi Hayashi et al.   Journal of Translational Medicine

The Role of Autophagy in Cancer: Therapeutic Implications

(2011) Z. J. Yang et al.   MOLECULAR CANCER THERAPEUTICS

HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer

(2009) L. M. Knowles et al.   CLINICAL CANCER RESEARCH

Heat shock proteins and immune system

(2009) Min-Fu Tsan et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Efficient Cross-presentation Depends on Autophagy in Tumor Cells

(2008) Y. Li et al.   CANCER RESEARCH

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

(2008) G. E. Peoples et al.   CLINICAL CANCER RESEARCH